Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Statistics
Share Statistics
Sagimet Biosciences has 30.67M shares outstanding. The number of shares has increased by -3.88% in one year.
| Shares Outstanding | 30.67M |
| Shares Change (YoY) | -3.88% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 55.55% |
| Shares Floating | 23.27M |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.96M, so 12.28% of the outstanding shares have been sold short.
| Short Interest | 3.96M |
| Short % of Shares Out | 12.28% |
| Short % of Float | 14.67% |
| Short Ratio (days to cover) | 13.33 |
Valuation Ratios
The PE ratio is -3.1 and the forward PE ratio is -0.5. Sagimet Biosciences's PEG ratio is 0.07.
| PE Ratio | -3.1 |
| Forward PE | -0.5 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 0.91 |
| P/FCF Ratio | -3.32 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sagimet Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.3, with a Debt / Equity ratio of 0.
| Current Ratio | 34.3 |
| Quick Ratio | 34.3 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.25M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -44.33% in the last 52 weeks. The beta is 2.43, so Sagimet Biosciences's price volatility has been higher than the market average.
| Beta | 2.43 |
| 52-Week Price Change | -44.33% |
| 50-Day Moving Average | 3.47 |
| 200-Day Moving Average | 3.99 |
| Relative Strength Index (RSI) | 35.32 |
| Average Volume (20 Days) | 638.73K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -54.45M |
| Net Income | -45.57M |
| EBITDA | -54.45M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 75.84M in cash and 78K in debt, giving a net cash position of 75.76M.
| Cash & Cash Equivalents | 75.84M |
| Total Debt | 78K |
| Net Cash | 75.76M |
| Retained Earnings | -295.31M |
| Total Assets | 160.26M |
| Working Capital | 148.32M |
Cash Flow
In the last 12 months, operating cash flow was -42.44M and capital expenditures 0, giving a free cash flow of -42.44M.
| Operating Cash Flow | -42.44M |
| Capital Expenditures | 0 |
| Free Cash Flow | -42.44M |
| FCF Per Share | -1.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SGMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SGMT is $31, which is 1302.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $31 |
| Price Target Difference | 1302.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 6.95 |
| Piotroski F-Score | 2 |